Commitment

BUILT ON
HUMIRA

HUMIRA is there for you and your patients, today and tomorrow

A commitment to robust clinical evidence

A group of people icon.

MORE THAN 1.4 MILLION PATIENTS have been prescribed HUMIRA worldwide across indications2

A pen and with notepad icon.

MORE THAN 100 GLOBAL CLINICAL TRIALS across US-approved indications3

An envelope with 2 letters icon.

HUMIRA has 350+ clinical trial publications and over 200 open-label publications4,*

*A literature search strategy was designed to find adalimumab publications parsed out by study type: open-label publications, meta-analyses, observational/registry studies, and randomized controlled trials (RCTs). Four databases in the ACSSTN command language platform were used: Medline, 1946 to January 17, 2020; Embase, 1947 to January 17, 2020; Biosis, 1926 to January 17, 2020; and HCAPLUS (Chemical Abstracts Plus), 1907 to January 17, 2020.

Innovations designed with the patient experience in mind

HUMIRA innovations—including the prefilled syringe and the HUMIRA Pen for self-injection, HUMIRA Citrate-free, and HUMIRA Complete patient support—designed with the patient experience in mind

2003


A syringe icon.

Prefilled syringe1,5

Offered patients an option to self-administer HUMIRA using a prefilled device

2006


HUMIRA Pen icon.

HUMIRA Pen1,6

Designed for ease of use, with patient self-administration in mind

2014


HUMIRA Complete icon.

HUMIRA Complete

Helping patients start and stay on track with their prescribed treatment plan

2018


A couple standing in front of a tree icon.

HUMIRA Citrate-free7,8,†

The majority of patients on HUMIRA today are taking HUMIRA Citrate-free, an innovation proven to offer less pain immediately following injection compared to HUMIRA 40 mg/0.8 mL presentations

HUMIRA is intended for use under the guidance and supervision of a physician. A patient may self-inject HUMIRA or a caregiver may inject HUMIRA if a physician determines that it is appropriate and with medical follow-up as necessary, after proper training in subcutaneous injection technique.

Trusted for 20 years and counting

HUMIRA has over 24 years of clinical trial experience starting in rheumatoid arthritis

1997


Clinical Trials Begin9

2002


FDA Approval
Moderate to Severe RA in Adults5

2003


First Adult Patient Enrolled in Plaque Psoriasis Clinical Trials10

2005


FDA Approval
Psoriatic Arthritis in Adults11

2006


FDA Approval
Ankylosing Spondylitis in Adults12

2007


FDA Approval
Moderate to Severe Crohn's Disease in Adults13

2008


FDA Approval
Moderate to Severe Juvenile Idiopathic Arthritis (age 4+)14

2008


FDA Approval
Moderate to Severe Chronic Plaque Psoriasis in Adults15

2012


FDA Approval
Moderate to Severe Ulcerative Colitis in Adults16

2014


FDA Approval
Polyarticular Juvenile Idiopathic Arthritis (age 2+)17

2014


FDA Approval
Moderate to Severe Pediatric Crohn’s Disease (age 6+)18

2015


FDA Approval
Moderate to Severe Hidradenitis Suppurativa in Adults19

2016


FDA Approval
Non-Infectious Intermediate, Posterior, and Panuveitis in Adults20

2017


FDA Approval
Data for Moderate to Severe Fingernail Psoriasis in Adults21

2018


FDA Approval
Label Expansion to Include Pediatric Patients (2+) With Non-Infectious Intermediate, Posterior, and Panuveitis22

2018


FDA Approval
Label Expansion to Include Adolescents (≥12) With Moderate to Severe HS23

2021


FDA Approval
Label Expansion to Include Pediatric Patients (5+) With Moderate to Severe Ulcerative Colitis24

First patient dosed April 1997 in rheumatoid arthritis.9